Nazarshodeh Elmira, Gharaghani Sajjad
Laboratory of Bioinformatics and Drug Design (LBD), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Laboratory of Bioinformatics and Drug Design (LBD), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
Biosystems. 2017 Dec;162:35-43. doi: 10.1016/j.biosystems.2017.09.005. Epub 2017 Sep 9.
Carbonic anhydrase isoform XII (CA XII) is a potential target for cancer treatment. In this study, pharmacophore modeling, hierarchical virtual screening, and toxicity risk analysis were performed for identifying novel CA XII inhibitors. A pharmacophore model of two classes of CA XII inhibitors was generated. The pharmacophore model indicated the important features of inhibitors for the binding with the CA XII. The model was then utilized to screen the ZINC and CoCoCo databases for retrieving potential hit compounds of CA XII. For accurate conclusions about the selectivity of inhibitors, the retrieved molecules which obey of Lipinski's rule of five (RO5) and have no toxicity risk were docked in a CA XII 3D structure by smina. Finally, on the basis of binding affinity and the binding mode of the molecules, twelve molecules were prioritized as promising hits. It should be noted that two of hits H5 and H6 were previously reported in the CHEMBL database. This hierarchical method is worthy of reducing the time and using almost all information available. The final hits may be used as a lead to discovery novel CA XII inhibitors.
碳酸酐酶同工酶XII(CA XII)是癌症治疗的一个潜在靶点。在本研究中,进行了药效团建模、分层虚拟筛选和毒性风险分析,以鉴定新型CA XII抑制剂。生成了两类CA XII抑制剂的药效团模型。该药效团模型表明了抑制剂与CA XII结合的重要特征。然后利用该模型在ZINC和CoCoCo数据库中筛选,以检索CA XII的潜在命中化合物。为了得出关于抑制剂选择性的准确结论,通过smina将符合Lipinski五规则(RO5)且无毒性风险的检索到的分子对接至CA XII 3D结构中。最后,根据分子的结合亲和力和结合模式,将十二个分子列为有前景的命中化合物。需要注意的是,命中化合物H5和H6中的两个先前已在CHEMBL数据库中报道。这种分层方法值得用于减少时间并利用几乎所有可用信息。最终的命中化合物可作为发现新型CA XII抑制剂的先导。